Komori
KYORIN Pharmaceutical (4569) · InitiativeAchieved

Improving Capital Efficiency and Increasing Shareholder Benefits through Share Repurchases and Cancellations

First written in FY2019-Q2. 2 of 4 entries say "Achieved", first in FY2019-Q3. Latest entry: FY2025.

4entries
8years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseCited as achievedFY20192018: 12019: 220192020: 020202021: 020212022: 020222023: 020232024: 020242025: 12025
Same theme, other companies
Shareholder Returns and Capital Policy through Treasury Share Acquisitions and CancellationsA theme 217 companies write about · 0 as a headwind · 218 as a tailwind

58 other companies' latest entry also says "Achieved".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 198 companies compared. The sentences above are computed from all 198.Comparing 200 of the theme's 219 threads.
Full recordFilings, disclosures and news, newest first
  1. FY2025AchievedAnnual report

    「To increase shareholder value by reducing the total number of shares issued, the company cancelled 4,662,295 treasury shares effective 30 May 2025.」

    The company cancelled 4,662,295 treasury shares on 30 May 2025, representing 7.2% of the total number of shares issued before the cancellation.
  2. FY2019Cited as achievedAnnual report

    「The company cancelled 10,339,692 treasury shares effective 30 November 2018.」

    The annual report cites the completion of the cancellation of the 10,339,692 shares scheduled for cancellation after the share repurchase.
  3. FY2019-Q3AchievedAnnual report

    「In addition, because the company cancelled treasury shares on 30 November 2018 pursuant to a resolution of the Board of Directors dated 5 November 2018, retained earnings and treasury shares each decreased by ¥25,330 million during the nine-month period ended in the third quarter of the current fiscal year.」

    The company cancelled the 10,339,692 shares scheduled for cancellation after the share repurchase on 30 November 2018, completing the cancellation of treasury shares.
  4. FY2019-Q2AdvancedAnnual report

    「Total number of shares to be acquired: 18,000,000 shares (maximum); total acquisition price: ¥44,352,000,000 (maximum); total shares acquired: 16,574,000 shares; acquisition price: ¥40,838,336,000; total shares to be cancelled: 10,339,692 shares; scheduled cancellation date: 30 November 2018.」

    To improve capital efficiency, the Company acquired 16,574,000 treasury shares for ¥40.838 billion and resolved to cancel 10,339,692 shares. The cancellation was scheduled as of the filing date.
Moved together

"Expanding the Generic Pharmaceutical Business Primarily through In-House Sales" moved the same way as this thread, in the same document, in 3 of its 4 moves.

322222★123456
  1. ★This thread
  2. 1Expanding the Generic Pharmaceutical Business Primarily through In-House Sales3×
  3. 2Expanding the Development Pipeline and Accelerating New Drug Development in 3 Priority Areas2×
  4. 3Expanding Product Offerings in Priority Areas through Active Licensing2×
  5. 4Decline in Upfront License Fees and Royalty Income2×
  6. 5Activating the Drug Discovery Platform through Open Innovation and New Technologies2×
  7. 6Reducing Selling, General and Administrative Expenses2×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
No upcoming earnings preview for KYORIN Pharmaceutical yet.
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.
Improving Capital Efficiency and Increasing Shareholder Benefits through Share Repurchases and Cancellations | KYORIN Pharmaceutical Co.,Ltd. (4569) | Komori